RxDoctor Payments Data

Catherine Makin, DO

Ophthalmology · New Braunfels, TXNPI 1932469251

Payments from drug & device makers

$6,238in general payments, 2019–2025

Across 188 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • AbbVie$1K
  • Rxsight Inc$541
  • Alcon$385
  • Amgen$294
  • Johnson & Johnson Surgical Vision, Inc.$198
  • plus $991 from 13 others

What the payments were for

  • Travel & lodging$99216%
  • Food & beverage$5,20383%
  • Gifts$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,238 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$593,464
Medicare patients
861
Services billed
3,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$70,661
LumiganBimatoprost84$48,596
Cyclosporine47$26,953
XiidraLifitegrast15$23,721
Alphagan PBrimonidine Tartrate29$13,446
RhopressaNetarsudil Mesylate36$12,672
TyrvayaVarenicline Tartrate16$10,407
Timolol Maleate123$9,219
CombiganBrimonidine Tartrate/Timolol25$8,784
VyzultaLatanoprostene Bunod18$7,511
Brimonidine Tartrate66$6,559
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$6,120
Brinzolamide23$4,105
SimbrinzaBrinzolamide/Brimonidine Tart20$3,953
Dorzolamide-TimololDorzolamide/Timolol/Pf21$3,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$1,417$141,487187 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$147$31,23233 claims
AlconSimbrinza$385$3,95320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →